Applying toxicogenomics in mechanistic and predictive toxicology

Toxicological Sciences

Volumn 83, Issue 2, 2005, Pages 205-206

  Cunningham, Michael L ^a   Lehman McKeeman, Lois ^b  

^a NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^b BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACYLSPHINGOSINE DEACYLASE; ADAPTOR RELATED PROTEIN COMPLEX 1 SIGMA 1; AMPHOPHILE; ANTIHISTAMINIC AGENT; CARRIER PROTEIN; CHLOROQUINE; ERYTHROMYCIN; GENTAMICIN; LYSOSOME ENZYME; SPHINGOMYELIN PHOSPHODIESTERASE; TAMOXIFEN; UNCLASSIFIED DRUG;

ACCURACY; DRUG INDUCED DISEASE; ELECTRON MICROSCOPY; GENE EXPRESSION; GENETIC SCREENING; GENOMICS; HUMAN; IN VITRO STUDY; INTERMETHOD COMPARISON; LAMELLAR BODY; LIPIDOSIS; MARKER GENE; MOLECULAR DYNAMICS; MOLECULAR GENETICS; NOTE; PATHOGENESIS; PREDICTION; TOXICOGENETICS; VALIDATION PROCESS;

ANIMALS; DRUG DESIGN; HUMANS; PREDICTIVE VALUE OF TESTS; RISK ASSESSMENT; TOXICOGENETICS; XENOBIOTICS;

EID: 13644252615     PISSN: 10966080     EISSN: None     Source Type: Journal    
DOI: 10.1093/toxsci/kfi047     Document Type: Note

References (10)

1. Cunningham, M. L., Bogdanffy, M. S., Zacharewski, T. R., and Hines, R. N. (2003). Workshop overview: Use of genomic data in risk assessment. Toxicol. Sci. 73, 209-215.
2. Halliwell, W. H. (1997). Cationic amphiphilic drug-induced phospholipidosis. Toxicol Pathol. 25, 53-60.
3. MacGregor, J. T. (2003). The future of regulatory toxicology: Impact of the biotechnology revolution. Toxicol. Sci. 75, 236-248.
4. Martin, W. J., II, Kachel, D. L., Vilen, T., and Natarajan, V. (1989). Mechanism of phospholipidosis in amiodarone pulmonary toxicity. J. Pharmacol. Exp. Ther. 251, 272-278.
5. Mortuza, G. B., Neville, W. A., Delany, J., Waterfield, C. J., and Camilleri, P. (2003). Characterization of a potential biomarker of phospholipidosis from amiodarone-treated rats. Biochim. Biophys. Acta 1631, 136-146.
6. Nelson, A. A., and Fitzhugh, O. G. (1948). Chloroquine: Pathological changes observed in rats which for two years had been fed various proportions. Arch. Pathol. 45, 454-462.
7. Nicholls, A. W., Nicholson, J. K., Haselden, J. N., and Waterfield, C. J. (2000). A metabonomic approach to the investigation of drug-induced phospholipidosis: An NMR spectroscopy and pattern recognition study. Biomarkers 5, 410-423.
8. Reasor, M. J. (1989). A review of the biology and toxicologic implications of the induction of lysosomal lamellar bodies by drugs. Toxicol. Appl. Pharmacol. 97, 47-56.
9. Reasor, M. J., and Kacew, S. (2001). Drug-induced phospholipidosis: Are there functional consequences? Exp. Biol. Med. Vet. 226, 825-830.
10. Sawada, H., Takami, K., and Asahi, S. (2004). A Toxicogenomic approach to drug-indiced phospholipidosis: Analysis of its induction mechanism and establishment of a novel in vitro screening system. Toxicol. Sci. 83, 282-292.